Showing 1301-1310 of 1477 results for "".
- Ocugen Completes Dosing of Subjects with Stargardt Disease in Cohort 2 of Phase 1/2 GARDian Clinical Trial of OCU410ST Gene Therapyhttps://modernod.com/news/ocugen-completes-dosing-of-subjects-with-stargardt-disease-in-cohort-2-of-phase-12-gardian-clinical-trial-of-ocu410st-gene-therapy/2482280/Ocugen announced that dosing is complete in the second cohort of its phase 1/2 GARDian clinical trial for OCU410ST (AAV-hRORA)—a modifier gene therapy candidate being developed for Stargardt disease as a one-time treatment. "The completion of dosing for Cohort 2 par
- Ora Inc. and Singapore Eye Research Institute Announce Partnershiphttps://modernod.com/news/ora-and-singapore-eye-research-institute-unveil-partnership-to-propel-ophthalmology-innovation-globally/2482264/Contract Research Organization (CRO) Ora Inc. announced a partnership with the Singapore Eye Research Institute (SERI) that aims to provide early-stage innovators with comprehensive research support. Financial terms of the deal were not disclosed.
- Pantheon Vision Announces Two Pre-Submission Meetings With the FDAhttps://modernod.com/news/pantheon-vision-announces-two-pre-submission-meetings-with-the-fda/2482235/Pantheon Vision said it has completed two successful pre-submission meetings with the FDA. Pantheon Vision requested these early interactions with the FDA review team to obtain agency guidance on preclinical and clinical work supporting a premarket approval (PMA) submission. P
- Orbis Partners and Heidelberg Engineering Partner to Train Eye Care Professionals Around the Worldhttps://modernod.com/news/orbis-partners-with-heidelberg-engineering-to-train-eye-care-professionals-around-the-world/2482223/Orbis has announced a new partnership with Heidelberg Engineering, which will fund teaching opportunities and research focused on training eye care professionals around the world via Cybersight—Orbis’s award-winning telemedicine and e-learning platform. It will als
- OcuTerra Fails Phase 2 DR:EAM Trial Evaluating Nesvategrast for Diabetic Retinopathyhttps://modernod.com/news/ocuterra-fails-phase-2-dream-trial-evaluating-nesvategrast-for-diabetic-retinopathy/2482163/OcuTerra Therapeutics announced topline results from its phase 2 DR:EAM (Diabetic Retinopathy: Early Active Management) clinical trial of nesvategrast (OTT166), a novel, selective RGD integrin inhibitor developed as an eye drop. The clinical trial did not meet its primary or key secondary ef
- Sylentis Fails Phase 3 Trial of RNAi-based Drug Candidate for Dry Eye Associated with Sjögren's Syndromehttps://modernod.com/news/sylentis-fails-phase-3-trial-of-rnai-based-drug-candidate-for-dry-eye-associated-with-sjogrens-syndrome/2482110/Sylentis, a subsidiary of Spain-based PharmaMar, announced that its phase 3 SYL10111_V (RNAi-based tivanisiran) clinical trial for the treatment of dry eye disease associated with Sjögren’s syndrome did not meet its primary endpoint—the signs and symptoms of DED. T
- Cell Types in the Eye Have Ancient Evolutionary Originshttps://modernod.com/news/cell-types-in-the-eye-have-ancient-evolutionary-origins/2482026/Karthik Shekhar of the Shekhar Lab at UC Berkeley and his colleagues raised a few eyebrows as they collected cow and pig eyes from Boston butchers, but those eyes—eventually from 17 separate species, including humans—are providing insights into the evolution of the vertebrate ret
- iHealthScreen Announces MHRA Certification and Registration for iPredict Automated AI Systemhttps://modernod.com/news/ihealthscreen-announces-mhra-certification-and-registration-for-ipredict-automated-ai-system/2481997/iHealthScreen has received UK Medicines and Healthcare Products Regulatory Agency (MHRA) certification and registration for its iPredict AI Eye Screening System, which is used for the early diagnosis of diabetic retinopathy (DR), age-related macular degeneration (AMD), and glaucoma. <
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- Signs of Glaucoma May Be Detectable Years in Advance of Disease Onsethttps://modernod.com/news/nih-signs-of-glaucoma-may-be-detectable-years-in-advance-of-disease-onset/2481989/Research funded by the National Eye Institute suggests that low density of pigment in the macula, the region of the retina required for sharp central vision, is associated with thinning of the retina and may serve as an early warning sign of glaucoma. The findings are based on nearly 400 women wh